Estimation of ALU Repetitive Elements in Plasma as a Cost-Effective Liquid Biopsy Tool for Disease Prognosis in Breast Cancer
Authors:
- Madhumathy G. NairMNMadhumathy G. Nair
- Rakesh S. RameshRRRakesh S. Ramesh
- Chandrakala M. NaiduCNChandrakala M. Naidu
- Apoorva D. MavatkarAMApoorva D. Mavatkar
- Snijesh V. P.SPSnijesh V. P.
- Vishakha RamamurthyVRVishakha Ramamurthy
- Vidya M. SomashekaraiahVSVidya M. Somashekaraiah
- Anupama C. E.AEAnupama C. E.
- Kiruthiga RaghunathanKRKiruthiga Raghunathan
- Anuradha PanigrahiAPAnuradha Panigrahi
- Manjula DasMDManjula Das
- Sujan K. DharSDSujan K. Dhar
Open Access
Abstract
Background: Liquid biopsy is widely recognized as an efficient diagnostic method in oncology for disease detection and monitoring. Though the examination of circulating tumor cells (CTC) is mostly implemented for the assessment of genomic aberrations, the need of complex methodologies for their detection has impeded its acceptance in low-resource settings. We evaluated cell-free DNA (cfDNA) as a liquid biopsy tool and investigated its utility in breast cancer patients. Methods: Total cell-free DNA was extracted from the plasma of breast cancer patients (n = 167) with a median follow-up of more than 5 years, at various stages of the disease. Quantitative PCR was performed to estimate the copy numbers of two fractions of ALU repetitive elements (ALU 115 and ALU 247), and DNA integrity (DI) was calculated as the ratio of ALU 247/115. Mutations in TP53 and PIK3CA in the cfDNA were estimated by next-gen sequencing (NGS) in a subset of samples. Associations of the levels of both the ALU fragments with various clinico-pathological factors and disease-free survival at various stages were examined. Nomogram models were constructed with clinical variables and ALU 247 levels to predict disease-free survival and the best performing model was evaluated by decision curve analysis. Results: DI and ALU 247 levels were significantly lower (p < 0.0001) in the post-operative plasma when compared to their pre-surgery levels. DI and ALU 247 were found to be significantly higher in patients with metastasis (p < 0.05). Patients with higher levels of ALU 247 in their post-operative plasma had significant poor disease-free survival (p = 0.005). Higher levels of ALU 247 in the circulation also correlated with low tumor-infiltrating lymphocytes (TIL) within their primary tumors in the ER-negative breast cancer subtype (p = 0.01). Cox proportional hazard analysis confirmed ALU 247 as an independent variable of disease-free survival both in univariate and multivariate analysis [HR 1.3 (95% CI 1.047 to 1.613, p = 0.017)]. The nomogram model showed that the addition of ALU 247 with other variables significantly improved (C-index 0.823) the predictive ability of the model. Conclusion: Our results confirm the utility of cfDNA as an evolving liquid biopsy tool for molecular analysis. Evaluation of larger fragments of cfDNA estimated through ALU 247 can provide vital information concurrent with the pathological process of disease evolution in breast cancer and warrants expansion to other cancer types.Keywords
All Related Versions
Funding Information
- Rajiv Gandhi University of Health Sciences (19MED070)
This publication has 42 references indexed in Scilit:
- Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancerTumor Biology, 2015
- Circulating cell-free DNA and its integrity as a prognostic marker for breast cancerSpringerPlus, 2015
- Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosisBreast Cancer Research and Treatment, 2014
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- Liquid Biopsies: Genotyping Circulating Tumor DNAJournal of Clinical Oncology, 2014
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- wANNOVAR: annotating genetic variants for personal genomes via the webJournal of Medical Genetics, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Prediction of Breast Tumor Progression by Integrity of Free Circulating DNA in SerumJournal of Clinical Oncology, 2006
- Serum Tumor Markers in Breast Cancer: Are They of Clinical Value?Clinical Chemistry, 2006